**Author details**

Bhargy Sharma and Konstantin Pervushin\* School of Biological Sciences, Nanyang Technological University, Singapore

\*Address all correspondence to: kpervushin@ntu.edu.sg

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**203**

*Neuroprotective Function of Non-Proteolytic Amyloid-β Chaperones in Alzheimer's Disease*

amyloid in Alzheimer's disease. Nature Structural & Molecular Biology.

Modulation of neurodegeneration by molecular chaperones. Nature Reviews.

[10] Chuang E, Hori AM, Hesketh CD, Shorter J. Amyloid assembly and disassembly. Journal of Cell Science.

[11] Anant K, Paravastu RDL, Yau W-M, Tycko R. Molecular structural basis for polymorphism in Alzheimer's β-amyloid fibrils. Proceedings of the National Academy of Sciences.

[12] Ahmed R, Melacini G. A solution NMR toolset to probe the molecular mechanisms of amyloid inhibitors. Chemical Communications (Camb).

[13] Rajamohamedsait HB, Sigurdsson EM. Histological staining of amyloid and pre-amyloid peptides and proteins in mouse tissue. Methods in Molecular

[14] Xue C, Lin TY, Chang D, Guo Z. Thioflavin T as an amyloid dye: Fibril quantification, optimal concentration and effect on aggregation. Royal Society

Open Science. 2017;**4**(1):160696

[15] Chen B, Thurber KR, Shewmaker F, Wickner RB, Tycko R. Measurement of amyloid fibril mass-per-length by tiltedbeam transmission electron microscopy. Proceedings of the National Academy of Sciences of the United States of America. 2009;**106**(34):14339-14344

[16] Wälti MA, Ravotti F, Arai H, Glabe CG, Wall JS, Böckmann A, et al. Atomic-

resolution structure of a diseaserelevant Aβ(1-42) amyloid fibril.

2015;**22**(6):499-505

2018;**131**(8):jcs189928

2008;**105**(47):18349-18354

2018;**54**(37):4644-4652

Biology. 2012;**849**:411-424

[9] Muchowski PJ, Wacker JL.

Neuroscience. 2005;**6**(1):11-22

*DOI: http://dx.doi.org/10.5772/intechopen.84238*

[1] Herguedas B, Garcia-Nafria J, Cais O, Fernandez-Leiro R, Krieger J,

organization of heteromeric AMPAtype glutamate receptors. Science.

[2] Iadanza MG, Jackson MP, Hewitt EW, Ranson NA, Radford SE. A new era for understanding amyloid structures and disease. Nature reviews Molecular Cell Biology. 2018;**19**(12):755-773

[3] Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's & Dementia. 2016;**12**(3):292-323

[4] Benjamin Dehay MB, Gorry P, Przedborski S, Vila M, Hunot S,

Mechanistic and therapeutic considerations. Lancet Neurology.

2015;**14**:855-866

2011;**286**(8):6291-6300

2017;**38**(9):1205-1235

2017;**46**(21):6492-6531

[8] Xiao Y, Ma B, McElheny D,

Singleton A, et al. Targeting α-synuclein for treatment of Parkinson's disease:

[5] Wei L, Jiang P, Xu W, Li H, Zhang H, Yan L, et al. The molecular basis of distinct aggregation pathways of islet amyloid polypeptide. The Journal of Biological Chemistry.

[6] Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K, et al. Amyloid beta: Structure, biology and structurebased therapeutic development.

[7] Ke PC, Sani MA, Ding F, Kakinen A, Javed I, Separovic F, et al. Implications of peptide assemblies in amyloid diseases. Chemical Society Reviews.

Parthasarathy S, Long F, Hoshi M, et al. Abeta(1-42) fibril structure illuminates self-recognition and replication of

Ho H, et al. Structure and

2016;**352**(6285):aad3873

**References**

*Neuroprotective Function of Non-Proteolytic Amyloid-β Chaperones in Alzheimer's Disease DOI: http://dx.doi.org/10.5772/intechopen.84238*
